NCT05871177View on ClinicalTrials.gov

Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 21, 2023

Primary Completion Date

May 24, 2024

Study Completion Date

May 24, 2024

Conditions
Peyronie Disease
Interventions
DEVICE

Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt

The medical device consists of a pre-filled syringe containing 3.2% Hyaluronic Acid Sodium Salt with high and low molecular weight \[32 mg (HHA) + 32 mg (LHA) / 2 ml\]

Trial Locations (3)

20122

Fondazione IRCSS Cà Granda Ospedale Maggiore Policlinico, Milan

Unknown

U.O.C. Urologia, Azienda Ospedaliero Universitaria Mater Domini di Catanzaro, Catanzaro

Azienda Ospedaliero Universitaria delle Marche, Macerata

All Listed Sponsors
lead

IBSA Farmaceutici Italia Srl

INDUSTRY

NCT05871177 - Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD) | Biotech Hunter | Biotech Hunter